<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1375">
  <stage>Registered</stage>
  <submitdate>16/11/2006</submitdate>
  <approvaldate>16/11/2006</approvaldate>
  <nctid>NCT00401739</nctid>
  <trial_identification>
    <studytitle>Safety, Tolerability and Pharmacokinetics of CSL360 in the Treatment of Acute Myeloid Leukemia</studytitle>
    <scientifictitle>Phase I Study of CSL360 in Patients With Relapsed, Refractory or High-Risk Acute Myeloid Leukemia</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CSLCT-AML-06-26</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Acute Myeloid Leukemia (AML)</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - CSL360

Experimental: I - Treatment with CSL360


Treatment: drugs: CSL360
Weekly IV Infusion. Dose escalation study.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Adverse events, pharmacokinetics</outcome>
      <timepoint>September 2009</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum tolerated dose</outcome>
      <timepoint>September 2009</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Partial, complete and overall response</outcome>
      <timepoint>September 2009</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Biological activity</outcome>
      <timepoint>September 2009</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Clinical diagnosis of acute myeloid leukemia

          -  Recent bone marrow biopsy

          -  Prior treatment or medically unfit for standard therapy</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Peripheral blood blast count &gt; 30 x 109/L, or rapidly progressive AML

          -  Previous solid organ transplant

          -  Active GvHD or immunosuppression

          -  Concurrent treatment with other anti-cancer therapy

          -  Active infections</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>40</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC</recruitmentstate>
    <hospital>Westmead Hospital - Westmead</hospital>
    <hospital>Royal Brisbane and Women's Hospital - Brisbane</hospital>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <hospital>Institute of Medical &amp; Veterinary Science - Adelaide</hospital>
    <hospital>Peter MacCallum Cancer Institute - Melbourne</hospital>
    <hospital>Royal Melbourne Hospital - Melbourne</hospital>
    <postcode>2145 - Westmead</postcode>
    <postcode>4029 - Brisbane</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3002 - Melbourne</postcode>
    <postcode>3052 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>CSL Limited</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Acute myeloid leukemia (AML) is a heterogeneous group of diseases characterized by
      uncontrolled proliferation of the myeloid line of white blood cells and impaired production
      of normal blood cells. If untreated, patients die of infection or bleeding usually in a
      matter of weeks. CSL360 is a neutralising monoclonal antibody which is believed to target the
      cells that are thought to drive AML but that are not effectively killed by standard
      treatment. The aims of the study are to determine a biologically active dose of CSL360 and
      generate understanding of a rational schedule of administration for future studies.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00401739</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Andrew Roberts, Dr</name>
      <address>Melbourne Health</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>